NEW TECH FOODS

Meatable has acquired UK start-up Uncommon Bio’s cultivated meat platform, along with its key technologies, patents, cell lines and several team members.

The deal gives Meatable access to Uncommon Bio’s non-GMO mRNA reprogramming and saRNA differentiation technologies, which will be integrated with its existing patented Opti-ox system. According to the company, the combination creates a “multi-platform” approach designed to accelerate product development, adapt to different markets and speed up regulatory approvals in multiple regions.

Uncommon Bio, formerly focused on cultivated pork and other meats, has shifted its focus to therapeutics. CEO Benjamina Bollag said Meatable was “the best home” for the company’s technology, adding that she looked forward to continued collaboration.

Meatable said the acquisition strengthens its position in the cultivated meat sector by expanding into species such as chicken, lamb and other high-flavour breeds, alongside its existing pork and beef lines. It also adds to the company’s intellectual property portfolio with additional patents and proprietary assets.

Jeff Tripician, CEO of Meatable, stated: “This acquisition is more than a strategic step – it sets a new standard for cultivated meat production. By combining two highly complementary platforms, Meatable is now equipped to reliably deliver high-quality cultivated meat at a global scale. This enables us to support the meat industry with a stable, secure, and future-proof supply of species like pork, beef, lamb and poultry, ensuring business continuity and resilience in the face of increasingly uncertain times.”

Meatable aims to work with supply chain partners to complement traditional livestock production, citing efficiency, scalability and the elimination of livestock disease risks as potential benefits.

Financial terms of the acquisition were not disclosed.

Top image: © Meatable